HALO
Price:
$58.47
Market Cap:
$7.44B
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to...[Read more]
Industry
Biotechnology
IPO Date
2004-03-16
Stock Exchange
NASDAQ
Ticker
HALO
According to Halozyme Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 156.40%. This represents a change of 201.39% compared to the average of 51.89% of the last 4 quarters.
The mean historical ROE of Halozyme Therapeutics, Inc. over the last ten years is 74.11%. The current 156.40% ROE has changed 111.05% with respect to the historical average. Over the past ten years (40 quarters), HALO's ROE was at its highest in in the September 2016 quarter at 241.38%. The ROE was at its lowest in in the June 2016 quarter at -270.92%.
Average
74.11%
Median
57.84%
Minimum
-165.35%
Maximum
336.00%
Discovering the peaks and valleys of Halozyme Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 182.26%
Maximum Annual ROE = 336.00%
Minimum Annual Increase = -523.15%
Minimum Annual ROE = -165.35%
Year | ROE | Change |
---|---|---|
2023 | 336.00% | 182.26% |
2022 | 119.04% | -41.78% |
2021 | 204.47% | 139.26% |
2020 | 85.46% | -208.56% |
2019 | -78.72% | 143.91% |
2018 | -32.28% | -206.80% |
2017 | 30.22% | -90.47% |
2016 | 317.18% | -523.15% |
2015 | -74.96% | -54.67% |
2014 | -165.35% | -139.60% |
The current ROE of Halozyme Therapeutics, Inc. (HALO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
219.84%
5-year avg
133.25%
10-year avg
74.11%
Halozyme Therapeutics, Inc.’s ROE is less than Agios Pharmaceuticals, Inc. (70.20%), less than Insmed Incorporated (1.26%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Ultragenyx Pharmaceutical Inc. (-266.02%), less than BioMarin Pharmaceutical Inc. (7.83%), greater than Seagen Inc. (-28.06%), less than Alnylam Pharmaceuticals, Inc. (323.66%), less than Exelixis, Inc. (21.26%), greater than Alector, Inc. (-102.63%), greater than Legend Biotech Corporation (-23.20%), less than Ascendis Pharma A/S (251.76%), less than Cytokinetics, Incorporated (196.01%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Blueprint Medicines Corporation (-47.66%), greater than BeiGene, Ltd. (-14.93%), less than Inhibrx Biosciences, Inc. (1.62%), less than Protagonist Therapeutics, Inc. (85.47%), greater than DICE Therapeutics, Inc. (-102.37%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Viridian Therapeutics, Inc. (-49.65%),
Company | ROE | Market cap |
---|---|---|
70.20% | $2.56B | |
1.26% | $12.18B | |
-98.94% | $8.19B | |
-266.02% | $4.71B | |
7.83% | $12.58B | |
-28.06% | $43.15B | |
323.66% | $34.82B | |
21.26% | $9.79B | |
-102.63% | $512.88M | |
-23.20% | $7.99B | |
251.76% | $7.21B | |
196.01% | $6.06B | |
-28.01% | $3.23B | |
-139.02% | $3.48B | |
-47.66% | $5.84B | |
-14.93% | $22.84B | |
1.62% | $225.10M | |
85.47% | $2.75B | |
-102.37% | $2.27B | |
-35.87% | $483.02M | |
-49.65% | $1.74B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Halozyme Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Halozyme Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Halozyme Therapeutics, Inc.'s ROE?
How is the ROE calculated for Halozyme Therapeutics, Inc. (HALO)?
What is the highest ROE for Halozyme Therapeutics, Inc. (HALO)?
What is the 3-year average ROE for Halozyme Therapeutics, Inc. (HALO)?
What is the 5-year average ROE for Halozyme Therapeutics, Inc. (HALO)?
How does the current ROE for Halozyme Therapeutics, Inc. (HALO) compare to its historical average?